Form 4: Tonix Pharmaceuticals Director Receives Stock Options

Director Richard Newcomb Stillwell was granted 22,700 stock options under the Tonix Pharmaceuticals 2026 Stock Incentive Plan.

Summary

• Director Richard Newcomb Stillwell received a grant of 22,700 stock options on May 12, 2026.
• The options have an exercise price of $13.28 per share.
• The options vest on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders.
• The options expire on May 12, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Granting of stock options results in potential future dilution for existing shareholders.

Risks

• Market volatility affecting the value of the underlying common stock.
• Potential for future dilution upon the exercise of these options.

Future Outlook

The options vest in one year, signaling a long-term retention strategy for the director.

Management Comments

• The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure leadership alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of a one-year vesting schedule is consistent with standard corporate governance practices for non-employee directors in small-cap biotech firms.

Corporate Governance

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on May 12, 2027.

Key Dates

Keywords

Tonix Pharmaceuticals, TNXP, Form 4, Insider Trading, Stock Options, Director Compensation